C Sixty

C Sixty is a preclinical-stage biotechnology company focused on developing a new class of fullerene-based antioxidants to treat diseases driven by oxidative stress. The company's proprietary platform utilizes C60 molecules, which act as high-capacity free radical scavengers and superoxide dismutase mimetics. Their therapeutic pipeline primarily targets neurodegenerative conditions such as Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease, as well as ophthalmological indications like Age-related Macular Degeneration (AMD). By leveraging the unique chemical properties of carbon nanostructures, C Sixty aims to provide potent, long-lasting protection against cellular damage caused by reactive oxygen species. The company was founded based on pioneering research from Rice University regarding water-soluble fullerene derivatives.